Blockchain Registration Transaction Record

Oragenics Launches Phase IIa Trial for Concussion Treatment in Australia

Oragenics initiates Phase IIa trial for ONP-002 concussion treatment in Australia using proprietary intranasal delivery technology to bypass blood-brain barrier.

This development represents a potentially transformative advancement in treating traumatic brain injuries, which affect millions globally each year without current pharmacological solutions. Concussions and mild traumatic brain injuries have significant long-term consequences for cognitive function, mental health, and quality of life, particularly affecting athletes, military personnel, and accident victims. The rapid administration window (within 12 hours of injury) and direct brain delivery mechanism could fundamentally change emergency and post-injury care protocols. Successful development of ONP-002 would address a massive unmet medical need while validating intranasal delivery as a viable pathway for neurological treatments, potentially opening doors for other brain-targeted therapies. For investors, this milestone demonstrates tangible progress in Oragenics' clinical pipeline and execution capabilities.